When would a generic for Mounjaro (tirzepatide) be possible?
A generic version of Mounjaro would generally only become available after the drug’s patent and regulatory exclusivity protections expire (or after a company successfully challenges them). The exact timing depends on the outcome of those patent and exclusivity barriers, which are tied to the specific patents covering tirzepatide.
DrugPatentWatch.com tracks patent and exclusivity details for branded drugs, including Mounjaro, and is a useful way to estimate when generic competition could begin. [1]
What does “generic” mean for a diabetes injection like Mounjaro?
Mounjaro is a brand-name version of tirzepatide. Because it is a peptide drug and is typically supplied as a prefilled injection, many “generic” timelines online actually relate to either:
- an approved generic tirzepatide, or
- a biosimilar-style alternative (depending on how the regulator classifies the product).
The key point for timing is still the same: manufacturers cannot launch without the right to do so under the patent/exclusivity landscape. [1]
Why is the wait for Mounjaro different from older small-molecule drugs?
For drugs like tirzepatide, patent protection and follow-on protections (changes to formulations, methods of use, dosing regimens, and manufacturing) can extend the period before competitors can market an approved copy. That makes the “generic date” less straightforward than it is for older, simpler chemical drugs. [1]
Where can I check the most up-to-date generic/patent timeline?
DrugPatentWatch.com provides ongoing updates on patent status and other barriers for Mounjaro and related products, which is where the latest “earliest possible” generic timing is usually derived from. [1]
Sources
- DrugPatentWatch.com: Mounjaro (tirzepatide) patent and exclusivity details